Biotech company Vitroscope, which develops technology to help researchers study immune activity, treatment responses and diseases in real time, has raised $7 million. The funding includes a $5 million Seed round and $2 million in non-dilutive funding.
The Seed round was co-led by Cerberus Ventures and YZR Capital, with participation from Arcas Ventures, Golden Egg Check, Devico Invest and angel investors Carles Reina, Fàtima Godall and Oskari Pétas.
The additional $2 million in non-dilutive funding comes from the Research Council of Norway. With this latest funding, Vitroscope has raised a total of $8.8 million to date.
Researchers are increasingly using advanced models, such as organoids and fresh human tissue, to study diseases and test new treatments. However, traditional laboratory plates cannot provide the steady flow of nutrients and oxygen that these living tissues need. This limits how long researchers can keep them alive and how much data they can collect during experiments.
Vitroscope has developed an automated perfusion platform that keeps living tissue supplied with a controlled flow of nutrients and oxygen. This allows researchers to run experiments for longer periods, collect more useful data and improve drug discovery research.
Carlo Kriesi, Co-founder and CEO of Vitroscope, says: “We started Vitroscope because living tissue cannot be reduced to a snapshot. Its behaviour depends on what is happening around it over time. With vitro.alive, researchers set those conditions themselves and follow how the tissue responds for days. This funding lets us bring this capability to more labs and extend it to higher-throughput experiments with vitro.scale.”
Vitroscope and Instant Bio used the vitro.alive platform to keep human brain organoids with blood vessel-like structures alive under controlled flow conditions for seven days. In another study, human liver cells formed organised tissue using the platform, while similar cells grown in standard laboratory plates did not show the same results.
A separate study using Vitroscope’s technology looked at kidney cells missing AdipoR1, a receptor linked to diabetic kidney disease. The results showed that these cells did not respond normally to the natural flow of fluids, helping researchers better understand how kidney diseases develop.
Chenny Zhang, Managing Director at Cerberus Ventures, says: “Biology isn’t static, but much of the way we study it still is. Vitroscope is changing that by enabling researchers to observe living tissue over time, generating the rich, longitudinal data that will become increasingly valuable in an AI-driven world.”
Markus Feuerecker, Founding and Managing Partner at YZR Capital, says: “Drug discovery and development need data that allows researchers to actually predict how patients will respond, and Vitroscope generates it at the source. Its platform is physical AI infrastructure: every experiment on living human tissue produces proprietary, comparable data that compounds over time. For us at YZR Capital, Vitroscope is a key building block in rewiring the pharma value chain, turning cell-level insight into human-relevant evidence long before the first clinical trial.
The funding will help Vitroscope bring its vitro.alive platform to market and further develop and test vitro.scale, its platform designed to handle more experiments at once. The company plans to start customer testing of vitro.scale in 2027, with a commercial launch expected in 2028.
